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Abstract 
Background: Activation of microglia is a feature of several neurodegenerative 
diseases. TREM2 is an immune receptor expressed by macrophages and microglia, 
which negatively regulates immune responses of these cells. Microglia-associated 
brain inflammation may be alleviated by up-regulation of microglial TREM2. 
However, it is unclear whether regulation of TREM2 expression in microglia is 
consistent with classical (M1) and alternative (M2) activation pathways of 
macrophages. Aims: To determine if microglial expression of TREM2 and its adaptor 
protein DAP12 is regulated by M1 or M2 activation. Methods: BV2 microglial cells 
were stimulated by LPS, IL-4, or HMGB1, respectively, with PBS as control. 6-hour 
and 24-hour stimulations were applied to each treatment. Expression of TREM2, 
DAP12, iNOS, IL-1β and Arg-1 was analysed by quantitative real-time PCR.  Relative 
quantification of results was performed using delta delta Ct method. One-sample 
Student’s t-test was used to detect difference between treatment and control. 
Results: Induced polarisation toward M1 and M2 activation phenotypes were 
confirmed in microglia. TREM2 was down regulated by LPS (Mean ± SD: 0.95±0.56 
for 6h and 0.40±0.07 for 24h) and up regulated by IL-4 (6h: 4.36±2.99; 24h: 
1.74±0.68) and HMGB1 (6h: 4.56±4.20; 24h: 1.20±0.20). DAP12 presented no 
obvious difference between treatments. Conclusion: Microglia are subjected to M1 
and M2 polarisation. M2 cytokine IL-4 up regulates both TREM2 and Arg-1, which 
attenuate brain inflammation. Regulation of microglial TREM2 provides a promising 
target for treatment of neurodegenerative diseases. 
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1 Introduction 
1.1 Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) 
1.1.1 Biology of TREM2 
Triggering receptors expressed on myeloid cells (TREMs) are cell surface receptors of 
immunoglobulin superfamily (Ig-SF). They are expressed primarily although not 
exclusively by cells of myeloid lineage. They were first identified by Bouchon and 
colleagues in neutophils and monocytes (Bouchon et al., 2000). The human TREM 
gene cluster is located at chromosome 6 and a TREM-related cluster was defined on 
mouse chromosome 17 (Daws et al., 2001). Two isoforms, TREM1 and TREM2, have 
been identified in humans. Orthologues of human TREM1 and TREM2 are expressed 
in mice as well as functional TREM3, which is a pseudogene in humans. 
TREMs are transmembrane glycoproteins consisting of an Ig-SF V-type extracellular 
domain, a transmembrane domain charged by lysine residue, and a short 
cytoplasmic domain without motifs for docking of signalling mediators. The 
positively charged transmembrane domain of TREM2 facilitates its association with 
adaptor DAP12, whose transmembrane domain contains a negatively charged 
aspartic acid residue (Daws et al., 2001). The cytoplasmic domain of DAP12 contains 
immunoreceptor tyrosine-based activation motifs (ITAMs). After being 
phosphorylated by the downstream signalling from DAP12, ITAMs recruit protein 
tyrosine kinases, initiating a sequential of phosphorylation events to regulate cellular 
activities. 
1.1.2 Functions of TREM2 
TREM2 has been identified on a variety of cells in myeloid lineage, including dendritic 
cells (DCs) (Bouchon et al., 2001), macrophages (Daws et al., 2001),  microglia 
(Schmid et al., 2002) and osteoclasts (Paloneva et al., 2003). It contributes to both 
non-immune and immune functions of these cells. The non-immune function is 
demonstrated by patients with Nasu-Hakola disease, also known as polycystic 
lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) 
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(Paloneva et al., 2003; Paloneva et al., 2002), which is characterised by pre-senile 
dementia and bone cysts and caused by loss-of-function mutations in the TREM2 
and/or DAP12 genes. Abnormalities in osteoclasts and microglia have been proposed 
to underlie the pathological features of the disease. The role of TREM2 in immune 
system is reflected by its relatively high expression on immuno-phagocytic cells
i
. 
Whereas TREM1 is a potent amplifier of pro-inflammatory responses (Bouchon et al., 
2001), TREM2 is a negative regulator of immune responses. Previous studies 
revealed that TREM2 attenuated inflammatory activities of macrophages (Daws et al., 
2001; Takahashi et al., 2005). TREM2- and/or DAP12- deficit macrophages have 
increased production of inflammatory cytokines, such as interferon-gamma (IFNγ) 
and inducible nitric oxygen synthase (iNOS) (Hamerman et al., 2005), and 
transduction of TREM2 led to reduced expression of them (Takahashi et al., 2005). 
An in vivo study in animal models of multiple sclerosis claimed that TREM2 
expression on microglia was enhanced during progression of the disease and 
blockade of TREM2 exacerbated the clinical symptoms (Ford and McVicar, 2009). 
These data suggest that modulation of TREM2 expression or function may provide 
novel insights into regulation of CNS inflammation. 
1.2 Macrophages in Immune Responses 
Macrophages are important cells in immune defence, tissue homeostasis and repair 
(Mosser and Edwards, 2008). They are highly versatile cells that can sense and 
respond to a huge variety of external signals. Accordingly, the activation of 
macrophages comprises a broad spectrum of responses. At each end of this 
spectrum, the phenotype of macrophage activation is broadly classified as classical 
or alternative, each of which is associated with distinct functional properties and 
profiles of activating cytokines (Classen A et al., 2009).  
                                                      
i
 Generally, DCs are phagocytes that initiate immune responses and are present in spleen, lymph nodes, skin and mucosal surfaces. The 
phagocytes circulating in peripheral blood are monocytes, while those tissue-resident phagocytes are known as macrophages. There are 
some tissue-specific macrophages, such as osteoclasts in bone and microglia in the CNS. 
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1.2.1 Classical Activation of Macrophages (M1) 
Classical activation of macrophages is typically associated with stimulation by Toll-
like receptor (TLR) ligands such as lipopolysaccharide (LPS) and/or the Th1 cytokine, 
IFNγ. These macrophages are important components of immune defence and 
inflammatory responses. Macrophages recognise invading pathogens via TLRs and 
produce iNOS. The latter facilitates synthesis of nitric oxide (NO) from L-arginine for 
pathogen killings. Classically activated macrophages also mediate Th1 immune 
responses by secreting pro-inflammatory cytokines, such as interleukin-1 beta (IL-1β) 
and tumor necrosis factor alpha (TNFα). Macrophages adopting this phenotype are 
commonly known as type-I activated macrophages (M1), which are highly 
microbicidal and pro-inflammatory. 
1.2.2 Alternative Activation of Macrophages (M2) 
Th2 cytokines-induced inflammatory macrophages exhibit an alternative activation 
phenotype distinct from that of M1 macrophages. These macrophages are, therefore, 
known as alternatively activated macrophages, or type-II activated macrophages 
(M2). They are characterised by enhanced capacity of phagocytosis, increased 
expression of MHC class II antigen, and reduced production of pro-inflammatory 
cytokines (Stein et al., 1992). Alternatively activated macrophages produce arginase-
1 (Arg-1) to metabolise L-arginine into polyamines and proline, which competes with 
iNOS for L-arginine and thus can prevent nitric oxide release. Polyamines are 
involved in cell growth and proliferation and proline is a component of collagen. In 
alternative activation, therefore, tissue repair is promoted whereas inflammatory 
responses are precluded. 
1.2.3 Regulatory Macrophages 
Some researchers described a third population of macrophages characterised by 
high production of IL-10 (Mosser and Zhang, 2008). These cells contribute to immune 
regulation of macrophage activities. Similar to classically activated macrophages, this 
population are induced by TLR stimulation but with different priming signals. These 
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activated macrophages exhibit increased production of iNOS but not Arg-1 (Edwards 
et al., 2006). Since these macrophages share the same activating stimulus (LPS) and 
immune product (iNOS) with M1 macrophages, they were not distinguished as a 
third population apart from M1 and M2 macrophages in the present study. 
1.3 Microglia, the Resident Macrophages in the Central Nervous 
System (CNS) 
1.3.1 Immune Activities of Microglia 
As a specialised subtype of macrophages, microglia are CNS-resident immune cells 
capable of phagocytosis and cytokine production. Their immune function is 
regulated by multiple signalling pathways that collectively determine the activation 
state. As surveillance cells, microglia play a dual role in the CNS. These phagocytes 
eliminate invading pathogens, apoptotic cells and tissue debris during 
neuropathology thus ameliorate inflammatory damages to brain tissues. On the 
other hand, they generate numerous cytokines and enzymes to mediate immune 
responses and brain inflammation. The balance of pro-inflammatory and anti-
inflammatory activities of microglia is crucial for brain homeostasis, which is 
determined by a number of intracellular pathways that transduce cell surface signals. 
An important example is the interplay between ITAM- and immunoreceptor 
tyrosine-based inhibition motif (ITIM)-mediated pathways. Dysfunction of microglia 
is a common characteristic of brain diseases, such as multiple sclerosis, Alzheimer's 
disease and brain ischaemia, et al. It is reported that regulation of over-activated 
microglia is a potential treatment strategy for these neurodegenerative pathologies 
(Osherovich, 2010; Takahashi et al., 2007; Yenari et al., 2010). 
1.3.2 TREM2-mediated Regulation of CNS Inflammation 
As described above, TREM2 is a negative regulator of immune responses of 
macrophages and recent evidence suggests microglial TREM2 restrains tissue-
damaging inflammation in the CNS. Accordingly, it is important to understand how 
microglial expression of TREM2 is regulated. Expression of TREM2 in macrophages is 
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attenuated by LPS stimulation and is enhanced in some macrophage subpopulations 
by exposure to IL-4 (Turnbull et al., 2006), but it is unclear whether similar pattern of 
TREM2 expression occurred in microglia. 
LPS is a component of gram-negative bacterial cell walls, and therefore mimics the 
classical activation of macrophages associated with bacterial infection. Non-
microbial activation of macrophages is also important in the context of sterile 
inflammatory conditions such as ischaemia and trauma. In these conditions, 
molecules released from necrotic cells, referred to as damage-associated molecular 
patterns (DAMPs) are detected by macrophages/microglia. One example is high-
mobility group box-1 (HMGB1), a pro-inflammatory cytokine (Ito et al., 2007) 
strongly implicated as a necrosis-induced DAMP, particularly in the brain. 
iNOS and IL-1β are potent mediators of immune defence of macrophages, and Arg-1 
is important in tissue repairing. In reference to classical and alternative activation of 
macrophages, iNOS and IL-1β were chosen as indicators for M1 activation and Arg-1 
as a signature marker for M2 activation of microglia.  
 
2 Aims 
The primary aim of this study was to determine if expression of TREM2 and its 
adaptor protein DAP12 is regulated in the microglial BV2 cell line by classical or 
alternative activation or HMGB1, a representative DAMP. Classical activation was 
induced by LPS and alternative activation by IL-4. To validate the expected 
polarisation of microglia towards an M1 or M2 phenotype, the expression of the M1 
genes iNOS and IL-1β and the M2 gene Arg-1 was also measured in the experiment.  
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3 Materials and Methods 
3.1 Materials 
3.1.1 Cells 
The BV2 cell line is a murine microglial culture immortalised by infection with a  
v-raf/v-myc recombinant retrovirus (Blasi et al., 1990). As they exhibit some 
properties of reactive microglia (phagocytic abilities and production of cytokines), 
BV2 cells have been extensively used as an in vitro culture system for microglia in 
published studies (Brautigam et al., 2005; Raouf et al., 2007; Watters et al., 2002). 
3.1.2 Reagents 
LPS and HMGB1 were used as M1-stimulating reagents, and IL-4 for M2-activation. 
LPS from Escherichia coli (serotype O127:B8) was purchased from Sigma-Aldrich Co., 
recombinant mouse IL-4 from R & D Systems Inc., and HMGB1 from HMGBiotech Srl. 
Dulbecco’s Phosphate Buffer Saline (PBS, Life Technologies) was used as the vehicle 
control. 
3.2 Methods 
3.2.1 Culturing and Passaging of BV2 Microglial Cells 
BV-2 cells were grown in Dulbecco’s Modified Eagle Media (DMEM, 500ml media 
with glucose 4500mg/L, L-glutamine, NaHCO3 and pyridoxine.HCl; Sigma) 
supplemented with 5% heat inactivated fetal calf serum (FCS, Sigma), 1% penicillin G 
and 1% streptomycin. Cells were cultured at 37°C in a humidified atmosphere 
containing 5% CO2. Media was changed completely every three days. Successive cell 
passages were performed by incubating cells in 0.4mM trypsin (2ml per 75T flask) at 
37°C for 30 seconds and detached cells by patting flasks. 6ml DMEM was added to 
inhibit trypsin. For 1:2 splitting, half of the cell suspension was transferred into a 
new flask and was resuspended with 8ml fresh DMEM with 5% FCS, 1% penicillin and 
1% streptomycin. 
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3.2.2 Immunocytochemistry 
BV2 cells were plated at 50,000 cells per well and incubated at 37°C in 5% CO2 for 24 
hours. Cells were thoroughly washed with PBS and then fixed with 4% 
paraformaldehyde (PFA) for 30 minutes. After fixation, cells were stored at 4°C in 
PBS for one week. Cells were permeabilised by 0.1% Triton-X100 (Sigma) at room 
temperature for 5 minutes and washed with PBS. 0.25% NH4Cl was used to quench 
autoflurescence. The non-specific binding sites were blocked with 5% mixed donkey 
and goat serum in blocking buffer (0.1% Bovine Serum Albumin Protein in PBS) for 
one hour.  
Ionized calcium binding adaptor molecule 1 (Iba1) was used as a marker of microglia 
(It is a protein specifically expressed by macrophages/microglia and is up regulated 
during the activation of these cells). BV2 cells were double-stained with either 
TREM2 and Iba1, or DAP12 and Iba1. Monoclonal antibodies (Abs) for 
immunostaining were purchased from R & D systems. Cells were incubated with the 
primary antibodies (Table 1) at room temperature for one hour and then washed 
with blocking buffer. The following procedures were conducted in the dark. Cells 
were incubated with fluorescence-coupled secondary antibodies (Table 1) at room 
temperature for one hour then washed with PBS. For counter staining, nuclei were 
stained with 4',6-diamidino-2-phenylindole (DAPI, 1:1000, Sigma) for 5 minutes. Cells 
were washed and stored in PBS at 4°C in the dark for 48 hours. Fluorescence images 
were collected at 630Χ magnification by confocal laser scanning microscopy (LSM 
710, Zeiss). Images were processed with ZEN 2009 Light Edition.  
Table 1: Antibodies for immunocytochemistry. 
Staining 
targets 
Primary antibodies  Secondary antibodies 
Abs Species Dilution  Abs Species Dilution 
TREM2 Anti-TREM2 rat 1:100  Anti-rat-568 goat 1:1000 
DAP12 Anti-DAP12  goat 1:100  Anti-goat-594 donkey 1:1000 
Iba1 Anti-Iba1 rabbit 1:250  Anti-rabbit-488 donkey 1:1000 
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3.2.3 Stimulation of BV2 Cells 
BV2 cells were seeded at 250,000 cells per well to 12-well plates. After incubation at 
37°C for 24 hours, media was replaced with 1ml serum-free DMEM supplemented 
with penicillin and streptomycin. After incubation for two hours, cells were 
stimulated with 1μg LPS, 20ng IL-4 or 100ng HMGB1, or PBS as control. Doses were 
selected based on previous experiments in the group. After incubation with the 
stimulating reagent at 37°C for 6 hours or24 hours, media was aspirated and 
replaced with PBS to wash cells. To precipitate RNA, 0.5ml per well TRIzol reagent 
(Life Technologies) was added for 2.5 minutes and, meanwhile, homogenised cell 
lysate by pipetting. Cell lysate was transferred to fresh tubes and stored at -70°C. 
3.2.4 RNA Extraction and Purification 
3.2.4.1 RNA Isolation from Stimulated BV2 Cells 
The cell lysate was thawed from -70°C. The amounts of reagents used in the 
following procedures were for 0.5ml TRIzol-suspended cell lysate per tube. 100μl 1-
Bromo-3-Choloropropane (BCP, Sigma) was added and incubated at room 
temperature for three minutes. Centrifuged at 12,000Χg at 4°C for 15 minutes to 
extract RNA into the upper translucent aqueous layer. Transferred the aqueous layer 
to a fresh tube. Added 100μl BCP to the aqueous layer and repeated the above steps 
of incubation and centrifuge. Added 1μl neat linear acrylamide (Life Technologies) 
and 250μl Isopropanol (Sigma) to precipitate RNA. Centrifuged at 12,000Χg at 4°C for 
10 minutes. Then removed the supernatant completely and washed RNA pellet with 
500μl 75% ethanol. Centrifuged at 7,500Χg at 4°C for 5 minutes. Removed 
supernatant completely and left the pellet to air dry until it became translucent. 
Resuspended the pellet with 40μl nuclease-free water (the volume depends on the 
size of pellet) and homogenised by pipetting. Then incubated at 55°C for 10 minutes 
and placed the tubes on ice.  
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3.2.4.2 DNase Treatment 
DNA-free kit (Life Technologies) was applied to remove residual genomic DNA that 
might be contained in RNA samples. For 40μl RNA suspension, 4μl (10% volume) 
10ΧDNase I Buffer (100mM Tris-HCl pH 7.5, 25mM MgCl2, 5mM CaCl2) and 1μl 
recombinant DNase I (2U/μl) were added and incubated at 37°C for 25 minutes. 
Then 4μl (10% volume) resuspended DNase inactivation reagent was added and 
incubated at room temperature for 2 minutes. Centrifuged at 10,000Χg at room 
temperature for 1.5 minutes and transferred the upper aqueous layer to a fresh tube. 
RNA concentration and purity were measured in NanoDrop Spectrophotometer ND-
1000 (NanoDrop Technologies). 
3.2.5 cDNA Synthesis by Reverse Transcription 
Reverse transcription of RNA was performed with Oligo (dT)15 primers and  
SuperScript III recerse transcriptase. Mastermix 1 was prepared for RNA samples 
extracted from cells with each treatment (LPS, IL-4, HMGB1 or PBS): 2μg RNA sample, 
2μl Oligo (dT)15 primers (0.5μg/μl, Promega), 2μl dNTP (10mM, Invitrogen), and 
topped up with nuclease-free water to 26μl. Incubated mastermix 1 in PCR thermal 
cycler T100 (BIO-RAD) at 65°C for 5 minutes to denature the secondary structures of 
RNA potentially formed in samples, and chilled on ice for 2 minutes. While matermix 
1 was being incubated, mastermix 2 was prepared: 8μl 5Χ First Strand Buffer 
(Invitrogen), 4μl Dithiothreitol (DTT, 0.1M, Invitrogen), 1μl RNasin Plus RNase 
inhibitor (40U/μl, Promega) and 1μl SuperScript III recerse transcriptase (200U/μl, 
Invitrogen). The mixture of mastermix 1 and Mastermix 2 was incubated at 50°C for 
50 minutes (for reverse transcription) and 70°C for 15 minutes (for inactivation of 
reverse transcriptase). Concentration and purity of the resulting cDNA was measured 
by NanoDrop and then stored at -20°C. 
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3.2.6 Quantitative Real-time PCR (qRT-PCR) Analysis for Expression of TREM2, 
DAP12 and Inflammatory Gene Transcripts 
3.2.6.1 Selection of Reference Genes 
In order to select reference genes that are stable under the experimental conditions, 
geNorm
PLUS
 analysis (http://www.biogazelle.com/genormplus) was performed by 
inputting information of samples (two for LPS, IL-4 and HMGB1 each) and choosing 
five candidate reference genes (18S rRNA, YWHAZ, Actin beta, GAPDH and B2M). 
3.2.6.2 Optimisation of Primers for Target Genes and Reference Genes 
Purified primers for target genes were generated (Invitrogen, Life Technologies) and 
optimised to an equal annealing temperature 60°C. Sequences of the first set of 
primers (Table 2) were retrieved from literature (Edwards et al., 2006; Kiialainen et 
al., 2005). Before performing experiment with BV2 cells, primer efficiencies were 
tested in splenocytes for TREM2 expression, with one M1 indicator iNOS, one M2 
indicator Arg-1 and one reference gene GAPDH. Ten-fold serial dilutions of cDNA 
were made (1000ng, 100ng, 10ng, 1ng, and 0.1ng). Primers efficiencies of both 
target genes and reference genes were tested by serial dilution qRT-PCR. Standard 
curves were constructed by the Ct (y-axis) versus log cDNA dilution (x-axis). The 
primer efficiency (E) of one cycle in the exponential phase was calculated according 
to the equation: E=10
-(1/slope)
-1 (Pfaffl, 2001). Poor specificity and efficiencies were 
obtained with the first set of primers (Table 2) which was likely because of the large 
product sizes. 
Table 2: The first set of primers for target genes. 
Target genes Primers Sequences (5’ to 3’) Length of products 
TREM2 Forward ATG GGA CCT CTC CAC CAG TTT CTC C  681 
Reverse CGT ACC TCC GGG TCC AGT GAG G 
iNOS Forward CCC TTC CGA AGT TTC TGG CAG CAG C 497 
Reverse GGC TGT CAG AGC CTC GTG GCT TTG G 
Arg-1 Forward CAG AAG AAT GGA AGA GTC AG 250 
Reverse CAG ATA TGC AGG GAG TCA CC 
GAPDH Forward GCA CTT GGC AAA ATG GAG AT 203 
Reverse CCA GCA TCA CCC CAT TAG AT 
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Therefore, a new set of primers (Table 3) were designed using NCBI Primer-Blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome) 
to produce a shorter product length and tested directly in BV2 cells. Two more genes 
(DAP12 and IL-1β) were included to validate the induced immune activities of BV2. 
With the result of geNorm analysis, B2M was used as a second reference gene in 
addition to GAPDH to provide a better normalisation.  
Table 3: The second set of primers for target genes. 
Target Primers Sequences (5’ to 3’) Length of products 
TREM2 Forward CTG CTG ATC ACA GCC CTG TCC CAA 108bp 
Reverse CCC CCA GTG CTT CAA GGC GTC ATA 
DAP12 Forward AGG CCC AGA GTG ACA CTT TCC CAA 109bp 
Reverse GCC AGG GCA ATC AGC AGA GTC A 
iNOS Forward GCG GAG TGA CGG CAA ACA TGA C  132bp 
Reverse AGG TCG ATG CAC AAC TGG GTG AAC 
IL-1β Forward CGA CAA AAT ACC TGT GGC CTT GGG C 108bp 
Reverse TGC TTG GGA TCC ACA CTC TCC AGC 
Arg-1 Forward GGA GAC CAC AGT CTG GCA GTT GGA 144bp 
Reverse GGA CAC AGG TTG CCC ATG CAG A 
GAPDH Forward TGC ATC CAC TGG TGC TGC CAA 140bp 
Reverse ACT TGG CAG GTT TCT CCA GGC G 
B2M Forward TGG CTC ACA CTG AAT TCA CCC CCA 100bp 
Reverse TCT CGA TCC CAG TAG ACG GTC TTG G 
 
3.2.6.3 ROX Reference Dye 
ROX (Invitrogen) was the reference dye used to normalise fluorescent reporter signal. 
The normalised reporter signal was calculated by dividing the reporter signal of SYBR 
Green I by the reference signal of ROX. The signal was then corrected for inter-well 
variables within the plate, such as sample amount variation and pipetting 
inaccuracies. 
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3.2.6.4 Quantitative Real-time PCR 
Each target gene along with reference genes (GAPDH and B2M) and no template 
control (primer control) was analysed in one plate for qRT-PCR. The qRT-PCR 
mastermix for each gene was prepared by the following reaction components: 12.5μl 
SYBR Green qPCR SuperMix (including Taq DNA polymerase, SYBR Green I dye, Tris-
HCl, KCl, 6mM MgCl2, 400μM dGTP, 400μM dCTP, 400μM dATP, 800μM dUTP, uracil 
DNA glycosylase (UDG) and stabilizers, Invitrogen), 1.25μl forward primer (10μM, 
Invitrogen), 1.25μl reverse primer (10μM, Invitrogen), 1μl ROX fluorescent dye 
(Invitrogen) and 8μl nuclease-free water. Mastermix (24μl) was filled in 0.2ml 96-
well plate (Thermo Scientific) followed by adding of 0.5μg cDNA as PCR templates. 
Wells were closed with strip caps, centrifuged and placed into PCR instrument 
(Stratagene Mx 3005P). The following PCR protocol was used: denaturation 
programme (95°C for 10 minutes), amplification programme repeated 40 cycles 
(denaturation: 95°C for 15 seconds, annealing: 60°C for 20 seconds, 72°C for 60 
seconds with a single fluorescence measurement), dissociation programme (95°C for 
60 seconds, 55°C for 30 seconds, 95°C for 30 seconds with a continuous fluorescence 
measurement) and a cooling programme to 40°C.  
3.2.7 Statistical Analysis 
For quantification of gene expression the cycle of threshold (Ct) for each gene 
transcript was determined. Ct is the point at which the fluorescence rises 
appropriately above the background fluorescence. The baseline signal and threshold 
signal of fluorescence were determined automatically by the PCR machine. 
Calculation was conducted in Microsoft Excel 2007. According to the delta delta-Ct 
method (Schmittgen and Livak, 2008), the relative expression ratio (RE) was 
calculated in relation to the expression of reference genes and was defined as 






ΔCtsample is the Ct difference of target-reference genes in treatment samples; 
ΔCt control is the Ct difference of target-reference genes in PBS control. 
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Geometrical mean of Ct values of two reference genes were calculated to normalise 
target genes (Vandesompele et al., 2002). Mean and standard deviation (SD) of RE 
values were calculated from three replicates of each treatment. One-sample 
Student’s t-test was performed in Graphpad Prism 5.0 to compare the difference of 
gene expression between the stimulated samples and PBS control, where the value 
of RE in PBS control was prescribed as 1. 
4 Results 
4.1 Optimisation of Primers and qRT-PCR 
4.1.1 Purity of RNA and cDNA 
Purity of RNA samples and cDNA templates was analysed by NanoDrop. For RNA 
samples, 260/280 values are > 1.8. 260/230 values range from 0.40 to 2.01. cDNA 
templates generated by reverse transcription from RNA samples have 260/280 
values > 1.85 and 260/230 values > 1.2. 
The ratio of absorbance at 260nm and 280nm is used for assessment of the purity of 
nucleic acids. It is generally accepted that a ratio 260/280 >1.8 indicates adequate 
purity. A reduced ratio may be caused by contamination with proteins or phenol that 
absorb strongly near 280nm. The ratio 260/230 is another measure of nucleic acid 
purity. Expected values of 260/230 range from 2.0 to 2.2, which is normally higher 
than the respective 260/280 values. A lower 260/230 ratio may indicate the 
presence of Ethylenediaminetetraacetic acid (EDTA), carbohydrates or phenol, which 
absorb near 230nm. However lower 260/230 do not interfere with the PCR reaction. 
In my experiment, both RNA and cDNA samples had desirable 260/280 ratios but 
lower 260/230. As TRIzol, a phenol-based reagent, was used to extract RNA from 
cells, the low 260/230 might be due to the contamination from this phenol reagent. 
However, 260/280 values at high purity level denied TRIzol contamination. Therefore, 
other contaminants (eg. carbohydrates) with absorbance at 230nm rather than 
phenol might present. Furthermore, 280/260 values of RNA above 2.0 demonstrate 
no genomic DNA contamination. Thus the RNA sample was thought to be of 
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sufficient quality for reverse transcription. As all cDNA 260/280 above 1.85 
theoretically exclude protein contamination, they were used as purified templates 
for qRT-PCR. 
4.1.2 Optimisation of Reference Genes 
When analysing results of qRT-PCR, several uncontrolled variables between samples 
can lead to misinterpretation of the results, such as different amounts of RNA and 
enzymatic efficiencies. In order to make a good comparison, normalisation to 
reference genes was used as a correction method for these variables. An adequate 
reference gene is expressed constantly at the same level throughout the experiment 
and between samples with different treatment. The geNorm analysis suggested 
GAPDH and B2M as two most stable reference genes under experimental conditions 
of the present study (Figure 1). 
 
Figure 1: M view of geNorm analysis for five candidate genes. A ranking of candidate genes is 
shown from most unstable gene at the left to the best reference genes at the right (stability 
increases from left to right: 18S rRNA, YWHAZ, Actin beta, GAPDH and B2M).  
4.1.3 PCR Specificity of Primers 
4.1.3.1 Specificity of the First Set of Primers 
With the first set of primers (Table 2), a few less sharp peaks appeared at low 
melting temperature before the final tall peak (green curves, Figure 2) in melting 
curves of both TREM2 (Figure 2A) and iNOS (Figure 2B) samples. Blunt peaks in 
melting curves of no template control (blue curves, Figure 2) indicate primer dimers, 
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and those of RNA control (red curves, Figure 2) indicate genomic DNA contamination. 
(No template control contained only primers without cDNA template; RNA control 
contained neither primers nor cDNA template, but only RNA samples without 
reverse transcription.)  
 
Figure 2: Melting curves of qRT-PCR for expression of TREM2 (A) and iNOS (B) in splenocytes. 
Blue curves: no template control; Red curves: RNA control; Green curves: samples with cDNA 
template. 
These PCR products of iNOS were documented by gel electrophoresis (Figure 3), the 
result of which was in agreement with findings from PCR. Reading the gel from right 
to left, the second well was loaded with 100bp DNA Ladder. A smear of products 
with large base pairs appeared in well 4 for RNA control (red arrow), well 8 for no 
template control (blue arrow) and well 12 for iNOS-treated sample (yellow arrow).  
In addition to the smear band in iNOS sample, there was a second brighter band 
(green arrow) with less base pairs approximately at the position of the expected 
length (497bp) of iNOS. 
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Figure 3: Electrophoresis of PCR products for iNOS expression in splenocytes. Yellow and green 
arrows: double-band products in iNOS samples; Red arrow: products in RNA control (no cDNA, 
no primer); Blue arrow: products in no template control (only primers, no cDNA template). 
4.1.3.2 Specificity of the Second Set of Primers 
To eliminate genomic DNA, DNase treatment was applied to RNA samples prior to 
the reverse transcription reaction and higher purity was obtained (260/280>2.0). To 
minimise primer dimer formation and improve PCR amplification efficiencies, 
sequences of primers were redesigned to generate a shorter product length. New 
primers were tested in BV2 cells and amplification specificity was proven by melting 
curves (Figure 4). The single distinct peak of melting curve for each gene indicates 
that a distinct single PCR product has been amplified. 
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Figure 4: Melting curves of qRT-PCR for target genes with optimised primers.  BV2 cells 
stimulated by LPS (red curves) or IL-4 (yellow curves) compared with PBS control (blue curves) 
and H2O control (horizontal curves). The single peak in melting curves of each gene indicates 
high specificity of primers.  
 
4.1.4 Efficiency of Real-time PCR 
Efficiency of qRT-PCR was calculated from standard curves of serial dilution PCR of 
cDNA (Figure 5). All the investigated transcripts showed good efficiencies: TREM2, 
E=89.4%; DAP12, E=93.4%; iNOS, E=92.5%; IL-1β, E=95.3%; Arg-1, E=96.2%; GAPDH, 
E=95.2%; and B2M, E=94.4%. Improved efficiency is probably due to the shorter 
length of products of the second set of primers (Table 3) than of those in the first set 
(Table 2), which enabled better amplification in PCR. 
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Figure 5: 10-fold serial dilution qRT-PCR for primer efficiencies. Graphs in the left column are 
amplification curves with diluted cDNA and those in the middle column are standard curves. The 
right column shows Ct values of each cDNA dilution for each gene.   
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As Ct values presented in amplification curves, Ct=20 occurred in samples with cDNA 
concentration ranged from 100ng/μl to 1000ng/μl. Therefore, 500ng/μl cDNA was 
used for later qRT-PCR analyses of target genes. 
4.2 Constitutive Expression of TREM2 in BV2 Cells 
To verify that BV2 cell constitutively express TREM2 and DAP12 and therefore 
provide a suitable system to study the regulation (up and down) of these genes, I 
performed immunocytochemistry. Expression of TREM2 (Figure 6) and DAP12 
(Figure 7) in non-stimulated BV2 cells was clearly observed. 
 
Figure 6: Immunocytochemistry of TREM2 expressed in unstimulated BV2 cells. The merged 
image exhibits TREM2 (red) with microglia marker Iba1 (green) and DAPI-stained nuclei (blue). 
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Figure 7: Immunocytochemistry of DAP12 expressed in unstimulated BV2 cells. The merged 
image exhibits DAP12 (red) with microglia marker Iba1 (green) and DAPI-stained nuclei (blue). 
 
4.3 M1- and M2- stimulated TREM2/DAP12 Expression in Microglia  
With all efficiencies are in range of 90% to 100%, the delta delta Ct method was 
adopted for relative quantification of PCR results. Relative expressions of genes are 
illustrated in Table 4. It should be noted that although statistical analysis has been 
carried out this is of an exploratory nature, because due to time constraints sample 
sizes (n = 3 independent cultures) are lower than needed to perform definitive 
comparisons in view of inter-culture variation. Therefore descriptions of changes in 
gene expression below are given with the above caveat in mind. 
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Table 4: Relative expressions (RE) of target genes. Mean and SD values of RE are 
calculated from three replicates of each treatment. 
Target genes Treatment  Relative Expression 
Hours Reagents  Mean SD P value 
TREM2 6h LPS  0.95 0.56 0.89 
IL-4  4.36 2.99 0.19 
HMGB1  4.56 4.20 0.28 
24h LPS  0.40 0.07 <0.01 
IL-4  1.74 0.68 0.20 
HMGB1  1.20 0.20 0.22 
DAP12 6h LPS  0.55 0.20 0.06 
IL-4  0.70 0.24 0.17 
HMGB1  0.97 0.26 0.87 
24h LPS  0.74 0.21 0.17 
IL-4  0.93 0.26 0.70 
HMGB1  1.25 0.58 0.54 
iNOS 6h LPS  1549.30 2093.78 0.33 
IL-4  44.96 33.50 0.15 
HMGB1  30.55 20.21 0.13 
24h LPS  3318.13 2829.52 0.18 
IL-4  35.76 12.42 0.04 
HMGB1  26.45 13.56 0.08 
IL-1β 6h LPS  318.58 209.33 0.12 
IL-4  1.95 0.40 0.05 
HMGB1  1.11 0.58 0.77 
24h LPS  207.82 152.89 0.14 
IL-4  2.90 1.64 0.18 
HMGB1  0.95 0.16 0.62 
Arg-1 6h LPS  0.87 0.34 0.57 
IL-4  159.91 90.92 0.09 
HMGB1  2.33 1.19 0.19 
24h LPS  0.60 0.27 0.13 
IL-4  591.20 669.65 0.27 
HMGB1  1.35 0.70 0.48 
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4.3.1 Expression of Inflammatory Mediators under M1 and M2 stimulation 
The expected polarisation toward M1 and M2 activation phenotypes by LPS and IL-4 
respectively were confirmed in BV2 microglial cells. Expression of both iNOS (Figure 
8A, 8B) and IL-1β (Figure 8C, 8D) was markedly increased in LPS samples, whereas 
Arg-1 expression was unaffected (Figure 8E, 8F). In contrast, a marked increase in 
Arg-1 expression with relatively modest increases in iNOS and IL-1β were observed in 
IL-4 –treated samples. HMGB1 stimulation produced no clear polarisation toward 
M1 or M2 phenotype, although an increase in iNOS expression is apparent.  
 
Figure 8: Relative expression of iNOS, IL-1β and Arg-1 in BV2 cells stimulated by LPS, IL-4 or 
HMGB1. A: iNOS expression by 6-hour stimulation; B: iNOS expression by 24-hour stimulation; C: 
IL-1β expression by 6-hour stimulation; D: IL-1β expression by 24-hour stimulation; E: Arg-1 
expression by 6-hour stimulation; F: Arg-1 expression by 24-hour stimulation. 
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4.3.2 Microglial TREM2 but Not DAP12 Expression is Regulated by M1 and M2 
Polarising Stimuli 
TREM2 expression (Figure 9A, 9B) in LPS stimulated BV2 cells was suppressed after 
24h but not 6h, but showed a trend towards an increase in expression by IL-4 after 
6h. DAP12 (Figure 9C, 9D) presented no obvious difference between treatments. 
 
Table 9: Relative expression of TREM2 and DAP12 in BV2 cells stimulated by LPS, IL-4 or HMGB1. 
A: TREM2 expression by 6-hour stimulation; B: TREM2 expression by 24-hour stimulation; C: 
DAP12 expression by 6-hour stimulation; D: DAP12 expression by 24-hour stimulation. 
By one-sample student’s t-test, 95% confidence interval (95% CI) of RE in all samples 
(except one, TREM2 expression in 24-hour LPS-stimulated sample) crossed 1 and P 
values were greater than 0.05. However, it was difficult to draw a definite conclusion 
that there was no difference between samples and control, because within the time 
allocated for the project it was possible to include only three replicates for each 
treatment group. 
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5 Discussion 
5.1 Validation of M1- and M2-activation in Microglia 
In BV2 microglia cells, iNOS was up regulated while Arg-1 was unaffected in LPS-
treated samples. Though IL-4 also promoted a more modest induction of iNOS, Arg-1 
expression was strongly induced in IL-4-treated samples. It is tempting to speculate 
that IL-4 -activated BV2 cells are not adept at killing microorganisms though they 
produce some iNOS, but rather their primary role is in tissue repair. In addition, iNOS 
expression was stable from 6h- to 24h-stimulation by IL-4, but Arg-1 exhibited a five-
fold increased expression with extended stimulation. It further indicates IL-4 as a 
positive regulator for Arg-1 expression. These finding are in agreement with previous 
studies with macrophages, in which M1 macrophages were activated by LPS and 
contributed to microbial killing and IL-4 induced M2 macrophages potentiated Arg-1 
expression and participated in tissue repair (Gordon, 2003; Hesse et al., 2001).  
IL-1β is a potent pro-inflammatory cytokine in responses to infection and 
inflammation. Macrophages are major peripheral sources of IL-1 and microglia are 
cells producing it in the CNS (van Dam et al., 1992). In both in vitro and in vivo 
studies, IL-1β was up regulated by LPS (Lee et al., 1993; Van Dam et al., 1995). This 
property was confirmed by my work, in which expression of IL-1β was three hundred 
times higher in LPS-treated samples compared with vehicle controls. As a pro-
inflammatory mediator, IL-1β exhibits a similar of induced expression to iNOS. A 
slight elevation of IL-1β expression was observed in IL-4-stimulated samples and an 
even minor increase HMGB1 samples. 
Collectively, these data suggest that BV2 microglia adopt similar phenotypes to 
macrophages in response to M1 and M2 activating stimuli. 
5.2 Association of M2 Phenotype with Activation and M1 Phenotype 
with Suppression of Microglial TREM2 Expression 
Since microglia are a subtype of macrophages, I anticipated  that microglial 
expression of TREM2 may be consistent with M1 and M2 activation patterns 
observed in macrophages. In this study, M1 activation with LPS and M2 activation 
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with IL-4 in BV2 microglial cells have been well established by the expression of iNOS 
and Arg-1. Therefore, the expression of TREM2 and DAP12 in microglia is discussed 
with reference to stimulation by these two reagents. A high level of expression of 
TREM2 by non-stimulated BV2 cells was demonstrated by immunocytochemistry 
analysis (Figure 6). The expression was down regulated by LPS and up regulated by 
IL-4. The reduced TREM2 expression in microglia by LPS was supported by the work 
of Schmid (Schmid et al., 2002). It is also consistent with another study of 
macrophages in which LPS abrogated and IL-4 promoted the expression of TREM2 
(Turnbull et al., 2006). Therefore, the association of microglial TREM2 expression 
with M2 activation and its inhibition by M1 signals mirrors the pattern observed in 
macrophages. 
5.3 Stable Expression of DAP12 
Unlike TREM2 regulated by LPS and IL-4, no obvious difference in DAP12 expression 
were observed between PBS controls and stimulated samples. A possible 
explanation is that DAP12 serves as an adaptor for both TREM1 and TREM2, which 
have contrary immune effects. TREM1 is a pro-inflammatory receptor and is up 
regulated by LPS, whereas TREM2 is, in contrast, anti-inflammatory and is down 
regulated by LPS (Bouchon et al., 2000). In an earlier mouse study (Kiialainen et al., 
2005), expression patterns of TREM2 and DAP12 during the CNS development were 
similar and even presented both temporal and spatial co-localization, however, 
DAP12 expression exceeded that of TREM2. The high constitutive expression of 
DAP12 and its less inducible property under inflammatory stimulation may reflect its 
role as an adaptor for both positive and negative regulators of inflammatory 
responses. 
5.4 TREM2/DAP12 Signalling in Microglia 
For each gene, expression in all samples was broadly consistent between 6-hour and 
24-hour stimulation. LPS-induced down-regulation of TREM2 co-existed with 
increased expression of iNOS and IL-1β. IL-4 promoted TREM2 expression was 
accompanied by enhanced production of Arg-1. The converse expression of iNOS and 
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Arg-1 appear to define two alternate functional states of microglia, involving M1 and 
M2 mediators, respectively.  
Molecules and mechanisms involved in TREM2/DAP12 dowmstream signalling may 
provide targets for regulation of TREM2 effects on microglia. ITAM-mediated DAP12 
signalling has been well established in NK cells (McVicar et al., 1998). It is reported 
that phosporylated ITAMs of DAP12 provide docking sites for tyrosine kinase ζ-chain 
associated protein 70 (ZAP70) and spleen tyrosine kinase (Syk), eliciting subsequent 
kinases cascades to activate p44/p42 extracellular-signal regulated kinase (ERK), 
phosphatidylinositol 3-kinase (PI3K) and phospholipase Cγ1 (PLCγ) pathways. These 
signals ultimately lead to intracellular Ca
2+
 mobilization, reorganisation of 
cytoskeleton and activation of transcription of immune mediators (Colonna, 2003).  
Similar DAP12 downstream signalling has been characterised in DCs and 
macrophages. As several downstream pathways are available for DAP12 signalling, it 
is important to work out certain molecules participating in TREM2/ DAP12-
mdediated cellular activities. ERK was reported to get involved in TREM2-triggered 
activation of DCs (Bouchon et al., 2001), however, whether TREM2-DAP12-ERK 
pathway occurs in macrophages is controversial. Hamerman et al. (Hamerman et al., 
2005) reported increased activation of ERK in DAP12 knockdown macrophages in 
response to LPS, while such activation was not observed in a study of TREM2 
knockdown cells (Turnbull et al., 2006). Conversely, an earlier study demonstrated 
that transduced stimulation of TREM2 in microglia induced phosphorylation of ERK 
(Takahashi et al., 2005). Thus, more research is needed to clarify the role of ERK in 
macrophage/microglia TREM2-DAP12 signalling. TREM-2 was reported to inhibit TLR- 
and FcR-induced macrophage responses (Hamerman et al., 2006). Another 
intracellular messenger involved in DAP12 signalling, PI3K, suppresses TLR activation 
(Fukao and Koyasu, 2003). Therefore, TREM2-DAP12-PI3K pathway may account for 
this inhibitory effect on macrophages, which down regulates TLR-mediated 
expression of iNOS and IL-1β. But it is interesting that, in my experiment, increased 
secretion of IL-1β occurred with both promotion and suppression of TREM2 
expression; whereas in a previous study, no difference of IL-1β expression was 
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identified between wild type microglia and those with TREM2 transduction 
(Takahashi et al., 2005). Therefore, such mechanisms are to be further investigated. 
In addition, expressions of iNOS and IL-1β shared a similar pattern upon different 
stimulation, which was significantly enhanced by LPS and moderately promoted by 
IL-4. Therefore, I speculated the presence of an association between iNOS and IL-1β. 
It is reported that IL-1β induced iNOS expression via NF-κB in astrocytes, another 
type of glial cells, and a NF-κB inhibitor suppressed iNOS production (Chao et al., 
1997). To study whether such mechanism could be applied to microglia, future work 
could be devoted to iNOS expression in both IL-1β-activated and inhibited microglia, 
and also by suppression of molecules involved in IL-1β/NF-κB signalling pathway.  
5.5 Clinical Perspectives: Microglial TREM2 and CNS Homeostasis 
Dysfunction of microglia is proposed to be a feature in neurodegenerative diseases. 
Hsieh et al. (Hsieh et al., 2009) identified certain ligands on neurons, which 
associated with TREM2 expressed on microglia to elucidate the removal of apoptotic 
neurons. Therefore, TREM2-mediated microglial phagocytosis may be essential for 
maintaining or restoring CNS homeostasis during development, ageing and 
pathology. Microglia eliminate tissue debris and dead cells therefore can minimise 
brain inflammatory changes with the potential to cause neuronal damage. However, 
microglia also play a detrimental role in brain diseases by promoting inflammation 
and activated microglia with overexpression of immune mediators could potentiate 
brain injury.  
In neuropathologies inflammation occurs as a local response initiated in part by 
microglia. It is controversial whether microglial activation and brain inflammation 
are beneficial or detrimental. On the one hand, activation of microglial phagocytosis 
without excessive cytokines production is important for surveillance of the CNS. On 
the other hand, activation of microglia is characteristic to most neurodegenerative 
diseases such as multiple sclerosis, Alzheimer’s disease and brain ischaemia (Carson 
et al., 2002; Dickson et al., 1993; Morioka et al., 1993). Pro-inflammatory cytokines 
IL-1β and TNFα secreted by activated microglia are potent mediators of neuronal 
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death in animal models of neurodegenerative diseases. Takahashi et al. (Takahashi 
et al., 2005) reported that TREM2-stimulated microglia had increased phagocytosis 
and retarded inflammatory activities. In his later work with experimental 
autoimmune encephalomyelitis (EAE) (Takahashi et al., 2007), an animal model of 
multiple sclerosis, intravenous transfusion of TREM2-transduced myeloid cells 
alleviated clinical symptoms in EAE-diseased mice. Therefore, TREM2 is a potential 
target for attenuation of microglia-mediated brain inflammation. In Alzheimer’s 
disease, microglia express cytokines, enzymes and receptors which are involved in 
degradation and phagocytosis of amyloid plaques. However, immune mediators 
secreted by microglia might also contribute to inflammatory impairment to brain. As 
TREM2 of microglia fulfils important functions in tissue debris clearance and 
resolution of inflammatory reactions, it might retard pathological processes of 
Alzheimer’s disease. Regulation of microglial TREM2 is also promising for brain 
ischaemia. It is implicated that inflammation is a secondary mechanism of brain 
injury following ischaemia. The microglial responses to ischaemic injury may be 
either beneficial by eliminating brain tissue debris or harmful by facilitating neuronal 
death. If regulation of microglia through TREM2 signalling pathway could be 
achieved, it will help attenuate brain inflammation and enhance tissue repair after 
ischaemic insults. 
There are several approaches to regulate TREM2-mediated immune activities of 
microglia. Genetic modification is a most direct intervention to regulate TREM2 
expression but its clinical application is limited by current technologies. The M1 and 
M2 polarising theory proposed in current study provide a more realistic strategy. It 
targets molecules involved in LPS and IL-4 activation of TREM2 expression. Although 
current work suggested that, in general, promoting an M2 environment is in favour 
of TREM2 expression, it remains unclear what signalling cascades and transcription 
factors are involved in M1 and M2 regulation of TREM2. Future work is expected to 
clarify such mechanisms. HMGB1-mediated DAMP-associated pathway might be 
another mechanism for TREM2 regulation, but such effects were not well illustrated 
due to insufficient data in this experiment. A third approach is to target TREM2 
ligands. Though have yet to be fully identified, certain anionic ligands identified in 
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bacteria and astrocytes associate to TREM2 via a charge-dependent interaction 
(Daws et al., 2003) and Heat Shock Protein 60 (HSP60) is another TREM2 ligand 
expressed on surface of neurons and astrocytes (Stefano et al., 2009). Mimic 
proteins of such ligands might play a role as TREM2 agonists. 
5.6 Limitations and Future Prospective 
This is the first study relating TREM2 expression in microglial cell line to M1 and M2 
types of inflammatory stimulation. This study has been constrained by the 12-week 
project period and most time has been devoted to optimise the experimental 
approaches. Should more time be allowed, sufficient data could be generated to 
provide more consistent and definitive results, in particular by increasing the 
number of replicates. However, this study still provides some valuable information 
for future studies, such as stable reference genes and high efficiency primers for 
related target genes. In addition, although the statistical analysis must be 
interpreted with some caution, the experiment has revealed a trend of inflammatory 
regulation of TREM2 expression and other immune responses in microglia. Further 
studies with a large sample of replicates and in vivo analysis may help to provide 
more detailed and reliable evidence to reveal regulation of microglial TREM2. 
Using an immortalised cell line instead of primary cells is another potential limitation 
of this study. Although BV2 cells recapitulate many properties of microglia, such as 
phagocytosis, they fail to model primary microglia in production of certain cytokines 
under certain stimulation. IL-1β is one of these cytokines that expressed different by 
activated BV2 cells and primary microglia. Horvath et al. (Horvath et al., 2008) 
reported that BV2 cells constitutively secreted IL-1β whereas primary microglia did 
not. It might be a possible explanation for a relatively lower expression of IL-1β 
compared to iNOS in LPS samples of the present work. Since BV2 cell line only 
partially models primary microglia, it will be important to replicate these data in 
primary microglia and also in vivo. 
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6 Conclusion 
Generally, BV2 microglial cells exhibit similar immune properties to macrophages 
following M1 and M2 inflammatory stimulation, respectively. The M2-polarising 
cytokine IL-4 induces up regulation of TREM2 and Arg-1, which are potentially 
important to attenuate brain inflammation and facilitate tissue repair. The M1 
activating reagent LPS stimulates production of pro-inflammatory mediators iNOS 
and IL-1β, and inhibits the expression of Arg-1 and TREM2. Regulation of microglial 
TREM2, particularly in the context of an environment favouring M2 polarisation, 
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